“The consumer space increasingly active and of course the healthcare space – healthcare broadly defined – pharmaceutical, equipment, services, the whole healthcare space undergoing a lot of scrutiny in terms of deals and just started to see the beginning of a lot of activity in chemicals,” Studzinski added.
Deals in the pharmaceutical, medical and biotech space is also at an all-time year-to-date high.
Additionally, the PowerShares Dynamic Biotechnology & Genome Portfolio (NYSEArca: PBE), BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC) and ALPS Medical Breakthroughs ETF (NYSEArca: SBIO) have all benefited from their tilt toward smaller biotech names that are developing new targeted treatments. [ETFs for the Next Biotech Takeover Targets]
For more information on the market sectors, visit our sector ETFs category.
Max Chen contributed to this article.